ストックスクリーナーアプリを入手
188.01
2.60%
-5.02
プレマーケット:
190.51
2.50
+1.33%
前日終値:
$193.03
開ける：
$191.8
24時間の取引高:
3.16M
Relative Volume:
0.51
時価総額：
$291.47B
収益：
$58.07B
当期純損益:
$9.40B
株価収益率:
62.43
EPS:
3.0115
ネットキャッシュフロー:
$9.87B
1週間 パフォーマンス:
-0.21%
1か月 パフォーマンス:
+98.64%
6か月 パフォーマンス:
+155.62%
1年 パフォーマンス:
+161.16%
1日の値動き範囲:
$187.06
$192.76
1週間の範囲:
$183.63
$193.97
52週間の値動き範囲:
$61.24
$193.97
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
188.01 | 299.25B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
LLY
Lilly Eli Co
|
1,044.67 | 947.09B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
238.64 | 578.21B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.26 | 394.89B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
157.05 | 298.47B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
MRK
Merck Co Inc
|
117.65 | 302.63B | 65.00B | 18.26B | 13.05B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
Strong cancer drug sales boost AstraZeneca earnings - Financial Times
Astrazeneca: Q4 Earnings Snapshot - kens5.com
AstraZeneca Sees Further Growth, Lifted by Cancer Drugs - bloomberg.com
BP halts buybacks; AstraZeneca lifts annual earnings - marketscreener.com
AstraZeneca Q4 And FY 2025: Strong Sales Growth And Pipeline Momentum - DirectorsTalk Interviews
Annual sales, profits jump at AstraZeneca - Sharecast.com
AstraZeneca Forecasts Continued Growth on Pipeline Strength - marketscreener.com
AstraZeneca forecasts 2026 sales, profit growth as Q4 meets expectations By Investing.com - Investing.com UK
AstraZeneca expects 2026 core EPS to increase by low double-digit percentage - marketscreener.com
AstraZeneca Forecasts Stronger Profits in 2026 on Cancer Drug Momentum - FXLeaders
AstraZeneca Logs Higher FY25 Profit, Revenue - marketscreener.com
AstraZeneca : Full Year and Q4 2025 results - marketscreener.com
Earnings Flash (AZN.L) AstraZeneca PLC Posts FY25 EPS $6.54 - marketscreener.com
AstraZeneca PLC Delivers Promising Financial Outlook - Devdiscourse
AstraZeneca's Q4 revenue up 4% to $15.5B - breakingthenews.net
Drugmaker AstraZeneca forecasts sales and profit growth in 2026 - marketscreener.com
AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth - Yahoo Finance UK
AstraZeneca forecasts growth in 2026 as it builds drug pipeline - Reuters
AstraZeneca PLC (LSE:AZN) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - TradingView
AstraZeneca earnings up next after NYSE debut, China expansion By Investing.com - Investing.com UK
A Look Ahead: AstraZeneca's Earnings Forecast - Benzinga
AstraZeneca bets big on China - fDi Intelligence
AstraZeneca's Evinova Enters Clinical Development AI Partnership Deal - marketscreener.com
Is AstraZeneca PLC Depositary Receipt stock risky to hold nowJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights- AZN - accessnewswire.com
AstraZeneca stock price: What could move AZN next week as earnings loom - TechStock²
AstraZeneca’s Stock Under Pressure: Is AZN’s Recent Slide A Buying Opportunity Or A Warning Sign - AD HOC NEWS
Deutsche Bank Maintains Sell on AstraZeneca PLC (AZN) Feb 2026 - Meyka
Week ahead: AstraZeneca, Unilver, BP results due - Sharecast.com
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance - FinancialContent
Stocks to watch next week: BP, Barclays, AstraZeneca, Airbnb and Coinbase - Yahoo Finance UK
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
AstraZeneca’s Precision Oncology Approach Applies To Deal, Portfolio Decisions - Citeline News & Insights
AstraZeneca (AZN) Among Major Drugmakers in Focus Amid Trump's D - GuruFocus
AstraZeneca opens on NYSE, expands in China - Cambridge Independent
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? - Yahoo Finance
AstraZeneca Full-Year 2025 Earnings Preview: 10 February 2026 - IG Group
AstraZeneca PLC (NASDAQ:AZN) announces strategic collaboration agreement with CSPC Pharmaceuticals - MSN
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $220.07 - 富途牛牛
Why AstraZeneca (AZN) dipped more than broader market today - MSN
Why Astrazeneca (AZN) Dipped More Than Broader Market Today - Yahoo Finance Singapore
AstraZeneca stock soared 103% Monday, holding at high level. Gets rating upgrade. - MSN
AstraZeneca PLCUpdate on Saphnelo subcutaneous administration - Research Tree
AstraZeneca (AZN) Faces FDA Setback for Lupus Drug Saphnelo - GuruFocus
Jim Cramer Says "I Like AstraZeneca Very Much" - Finviz
AstraZeneca (AZN) Stock Surges Over 100% - GuruFocus
Astrazeneca plc Provides Update on US Regulatory Review of Saphnelo Subcutaneous Administration in Systemic Lupus Erythematosus - marketscreener.com
Astrazeneca doubles down on China with $15B+ investments - BioWorld MedTech
Jim Cramer says "I like AstraZeneca very much" - MSN
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
3.51%
0.40%
大文字化:
|
ボリューム (24 時間):